Literature DB >> 15558018

CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase.

Naoko Suenaga1, Hidetoshi Mori, Yoshifumi Itoh, Motoharu Seiki.   

Abstract

Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a potent modulator of pericellular environment through its proteolytic activity and promotes migration, invasion, and proliferation of tumor cells. During cell migration, MT1-MMP binds to CD44H, a major hyaluronan receptor, through the hemopexin-like (HPX) domain and localizes at the migration front. MT1-MMP is also responsible for shedding CD44H, which supports CD44H-mediated cell migration. In this study, we asked whether the binding of MT1-MMP to CD44H is a prerequisite step for the successive shedding. Deletion of the HPX domain deprived MT1-MMP of its shedding activity. Furthermore, disruption of the CD44H/MT1-MMP complex by overexpressing the HPX fragments resulted in inhibition of the shedding. Thus, the CD44H in the complex appears to be the direct substrate of MT1-MMP for shedding. Interestingly, other members of the MT-MMP family showed varied extents of CD44H shedding. Domain swapping between MT1-MMP and other MT-MMPs revealed that the ability of the HPX domains to bind CD44H is conserved among them. However, the shedding activity was different depending on the catalytic domains. The conserved binding ability of the HPX domains suggests that CD44H may act as a core molecule assembling multiple MT-MMPs on the cell surface.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15558018     DOI: 10.1038/sj.onc.1208258

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Comparison of metalloproteinase protein and activity profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  Anal Biochem       Date:  2010-10-23       Impact factor: 3.365

2.  Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.

Authors:  Gillian Murphy
Journal:  Int J Exp Pathol       Date:  2010-08       Impact factor: 1.925

3.  Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration.

Authors:  Toshiyuki Murai; Yuusuke Maruyama; Kazuhiro Mio; Hidetoshi Nishiyama; Mitsuo Suga; Chikara Sato
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

Review 4.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 5.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 6.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 7.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

Review 8.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 9.  Peripheral membrane associations of matrix metalloproteinases.

Authors:  Steven R Van Doren; Tara C Marcink; Rama K Koppisetti; Alexander Jurkevich; Yan G Fulcher
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-23       Impact factor: 4.739

Review 10.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.